2023 World Conference on Lung Cancer (Posters)-EP09.03. Outcomes of Extracranial SBRT for Induced Oligopersistant and Oligoprogressive NSCLC Combined with Novel Systemic Therapies

EP09.03. Outcomes of Extracranial SBRT for Induced Oligopersistant and Oligoprogressive NSCLC Combined with Novel Systemic Therapies - PDF(Slides)

Back to course

Pdf Summary

This research poster presentation discusses the outcomes of using stereotactic body radiation therapy (SBRT) combined with novel systemic therapies for patients with induced oligopersistant disease (OpersisD) or oligoprogressive disease (OprogD) in Stage IV non-small cell lung cancer (NSCLC). The study looked at 49 patients who received SBRT while being treated with Osimertinib or immunotherapy agents. The outcomes measured included progression-free survival (PFS), time to change of systemic treatment (TTCST), overall survival (OS), local control (LC), and treatment-related toxicity.<br /><br />The results showed that SBRT for OpersisD or OprogD in Stage IV NSCLC patients while on targeted therapy or immunotherapy resulted in high local control rates and appeared to be safe. It also may have lengthened the time before switching to a new systemic therapy. Median follow-up time from first SBRT was 18.8 months, and LC was achieved in 92.2% of treated lesions. 67.3% of patients experienced radiographic progression, but salvage SBRT was able to be given to 13 of them. Systemic treatment was changed for 51% of patients due to disease progression at a median time of 11.8 months.<br /><br />The study found that OpersisD compared to OprogD had a longer median PFS (18.3 months versus 6.1 months) and longer median TTCST (23.6 months versus 13.5 months). Only 2% of patients experienced grade 3 pneumonitis after SBRT, and no grade 4-5 toxicities were reported. The study also conducted a multivariate analysis which showed that the type of systemic agent used, OprogD versus OpersisD, and other factors had an impact on PFS and TTCST.<br /><br />In conclusion, this study suggests that combining SBRT with novel systemic therapies for OpersisD or OprogD in Stage IV NSCLC patients may be a promising approach. However, further prospective studies are warranted to validate these findings.

Asset Subtitle

Philip Blumenfeld

Meta Tag

Speaker Philip Blumenfeld

Topic Metastatic NSCLC: Local Therapies - OIigometastatic NSCLC

Keywords

stereotactic body radiation therapy

SBRT

systemic therapies

oligopersistant disease

OpersisD

oligoprogressive disease

OprogD

non-small cell lung cancer

NSCLC

immunotherapy agents